If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]
GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the serious consequences of COVID-19, (PASC, post-COVID or long COVID), announces today that its scientific director, Dr. Hervé Perron, has unveiled new data further documenting the presence of W-ENV in post-COVID patient cohorts during the 18th symposium of the International Society of Neuro-Virology which was held from October 11 to 14, 2022.